Effect of L-arginine supplementation on insulin resistance and serum adiponectin concentration in rats with fat diet

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 7, 2015, Pages 10358-10366

  Miczke, Anna ^a   Suliburska, Joanna ^b   Pupek Musialik, Danuta ^a   Ostrowska, Lucyna ^c   Jabłecka, Anna ^a   Krejpcio, Zbigniew ^b   Skrypnik, Damian ^a   Bogdański, Paweł ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

High fat (HF) diet; Insulin resistance; L arginine supplementation; Nitric oxide; Serum adiponectin

Indexed keywords

ADIPONECTIN; ARGININE; CHOLESTEROL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEXOKINASE; INSULIN; NITRIC OXIDE; THIOPENTAL; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CALORIC INTAKE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMA IR; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; NONHUMAN; NUTRITIONAL PARAMETERS; RAT; WEIGHT GAIN;

EID: 84940676186     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA and Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
2. Llorens S, Jordan J and Nava E. The nitric oxide pathway in the cardiovascular system. J Physiol Biochem 2002; 58: 179-188.
3. Zhou L and Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009; 20: 223-230.
4. Gudi T, Hong GK, Vaandrager AB, Lohmann SM and Pilz RB. Nitric oxide and cGMP regulate gene expression in neuronal and glial cells by activating type II cGMP-dependent protein kinase. FASEB J 1999; 13: 2143-2152.
5. Alheid U, Frolich JC and Forstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res 1987; 47: 561-571.
6. Arndt H, Smith CW and Granger DN. Leukocyte-endothelial cell adhesion in spontaneously hypertensive and normotensive rats. Hyper-tension 1993; 21: 667-673.
7. Drexler H, Zeiher AM, Meinzer K and Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
8. Imaizumi T, Hirooka Y, Masaki H, Harada S, Momohara M, Tagawa T and Takeshita A. Effects of L-arginine on forearm vessels and responses to acetylcholine. Hypertension 1992; 20: 511-517.
9. Pieper G, Siebeneich W and Dondlinger L. Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur J Pharmacol 1996; 317: 317-320.
10. Closs EI, Scheld JS, Sharafi M and Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino-acid transporters. Mol Pharmacol 2000; 57: 68-74.
11. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M and Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1991; 88: 10480-10484.
12. Alvares TS, Conte-Junior CA, Silva JT, Margaret V and Paschoalin F. Acute L-arginine supplementation does not increase nitric oxide production in Healthy subjects. Nutr Metab 2012; 9: 54.
13. Bode-Boger SM, Scalera F and Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007; 114: 295-306.
14. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Maraguchi M, Ohmoto Y, Funahashi T and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
15. Shimada K, Miyazaki T and Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 2004; 344: 1-12.
16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda N, Nishida M, Kihara S, Sakai N, Nakaijma T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
17. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE and Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
18. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB and Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
19. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y and Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hyper-tension 2004; 43: 1318-1323.
20. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A and Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
21. Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, Kawano Y, Funahashi T and Ogihara T. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006; 98: 1603-1608.
22. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T and Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-2049.
23. Fujita K, Maeda N, Sonoda M, Ohashi K, Hibuse T, Nishizawa H, Nishida M, Hiuge A, Kurata A, Kihara S, Shimomura I and Funahashi T. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol 2008; 28: 863-870.
24. Dobutović B, Smiljanić K, Soskić S, Düngen HD and Isenović ER. Nitric oxide and its role in cardiovascular diseases. The Open Nitric Oxide Journal 2011; 3: 65-71.
25. Bourgoin F, Bachelard H, Badeau M, Melancon S, Pitre M, Lariviere R and Nadeau A. Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet. Am J Physiol Heart Circ Physiol 2008; 295: H1044-1055.
26. Shaker O, Ghallab Na, Hamdy E and Sayed S. Inducible nitric oxide synthase (iNOS) in gingivial tissues of chronic peridontitis with and without diabetes immunohistochemistry and RT-PCR study. Arch Oral Biol 2013; 58: 1397-1406.
27. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ and Ma XL. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Cir-culation 2007; 115: 1408-1416.
28. Gonon AT, Widegren U, Bulhak A, Salehzadeh F, Persson J, Sjoquist PO and Pernow J. Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt and nitric oxide. Cardiovasc Res 2008; 78: 116-122.
29. Flynn NE, Meininger CJ, Haynes TE and Wu G. The metabolic basis of arginine nutrition and pharmacotherapy. Biomed Pharmacother 2002; 56: 427-438.
30. Edmonds MS, Gonyou HW and Baker DH. Effect of excess levels of methionine, tryptophan, arginine, lysine or threonine on growth and dietary choice in the pig. J Anim Sci 1987; 65: 179-185.
31. Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 1997; 127: 838-841.
32. Jobgen W, Meininger CJ, Jobgen SC, Li P, Lee MJ, Smith SB, Spencer TE, Fried SK and Wu G. Dietary L-arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in diet-induces obese rats. J Nutr 2009; 139: 230-237.
33. Bogdański P, Suliburska J, Grabańska K, Musialik K, Cieślewicz A, Skołuda A and Jabłecka A. Effect of 3 months L-arginine supplementation on insulin resistance and tumor necrosis factor activity in patients with visceral obesity. Eur Rev Med Pharmacol Sci 2012; 16: 816-823.
34. De Castro Barbosa T, Lourenço Poyares L, Fabres Machado U and Nunes MT. Chronic oral administration of arginine induces GH gene expression and insulin resistance. Life Sci 2006; 79: 1444-1449.
35. Kawano T, Nomura M, Nisikado A, Nakaya Y and Ito S. Supplementation of L-arginine improves hypertension and lipid metabolism but not insulin resistance in diabetic rats. Life Sci 2003; 73: 3017-3026.
36. Lucotti P, Setola E, Monti LD, Galluccio E, Costa S, Sandoli EP, Fermo I, Rabaiotti G, Gatti R and Piatti P. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab 2006; 291: 906-912.
37. Lucotti P, Monti L, Setola E, La Canna G, Castiglioni A, Rossodivita A, Pala M, Formica F, Paolini G, Catapano Al, Bosi E, Alfieri O and Piatti P. Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. Metabolism 2009; 58: 1270-1276.
38. Bogdański P, Szulińska M, Suliburska J, Pupek-Musialik D, Jabłecka A and Witmanowski HJ. Supplementation with L-arginine favorably influences plasminogen activator inhibitor type 1 concentration in obese patients. A randomized, double blind trial. Endocrinol Invest 2013; 36: 221-226.
39. Claybaugh T, Decker S, Mcall K, Slyvka Y, Steimle J, Wood A, Schaefer M, Thuma J and Inman S. L-arginine supplementation in type II diabetic rats preserves renal function and improves insulin sensitivity by altering the nitric oxide pathway. Int J Endoc 2014; 2014: 171-546.
40. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY and Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
41. Cardillo C, Campia U, Bryant MB and Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106: 1783-1787.
42. Piatti PM, Monti LD, Zavaroni I, Valsecchi G, Van Phan C, Costa S, Conti M, Sandoli E, Solerte B, Pozza G, Pontiroli AE and Reaven G. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2416-2420.
43. Hattori S, Hattori Y and Kasai K. Hypoadiponectinemia is caused by chronic blockade of nitric oxide synthesis in rats. Metabolism 2005; 54: 482-487.
44. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M and Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
45. Míguez I, Mariño G, Rodríguez B and Taboada C. Effects of dietary L-arginine supplementation on serum lipids and intestinal enzyme activities in diabetic rats. J Physiol Biochem 2004; 60: 31-37.
46. Saleh AI, Abdel Maksoud SM, El-Maraghy SA and Gad MZ. Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin. J Cardiovasc Pharmacol Ther 2011; 16: 53-62.
47. Tripathi P and Misra MK. Therapeutic role of L-arginine on free radical scavenging system in ischemic heart diseases. Indian J Biochem Biophys 2009; 46: 498-502.
48. Tan B, Yin Y, Liu Z, Tang W, Xu H, Kong X, Li X, Yao K, Gu W, Smith SB and Wu G. Dietary L-arginine supplementation differentially regulates expression of lipid-metabolic genes in porcine adipose tissue and skeletal muscle. J Nutr Biochem 2011; 22: 441-445.